Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration.


Journal

Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169

Informations de publication

Date de publication:
02 2020
Historique:
received: 23 05 2019
revised: 11 10 2019
accepted: 22 10 2019
pubmed: 2 11 2019
medline: 14 1 2021
entrez: 1 11 2019
Statut: ppublish

Résumé

Synapse impairment is thought to be an early event in Alzheimer's disease (AD); dysfunction and loss of synapses are linked to cognitive symptoms that precede neuronal loss and neurodegeneration. Neurogranin (Ng) is a somatodendritic protein that has been shown to be reduced in brain tissue but increased in the cerebrospinal fluid (CSF) of AD patients compared to age-matched controls. High levels of CSF Ng have been shown to reflect a more rapid AD progression. To gauge the translational value of Ng as a biomarker, we developed a new, highly sensitive, digital enzyme-linked immunosorbent assay (ELISA) on the Simoa platform to measure Ng in both mouse and human CSF. We investigated and confirmed that Ng levels are increased in the CSF of patients with AD compared to controls. In addition, we explored how Ng is altered in the brain and CSF of transgenic mice that display progressive neuronal loss and synaptic degeneration following the induction of p25 overexpression. In this model, we found that Ng levels increased in CSF when neurodegeneration was induced, peaking after 2 weeks, while they decreased in brain. Our data suggest that CSF Ng is a biomarker of synaptic degeneration with translational value.

Identifiants

pubmed: 31669672
pii: S0969-9961(19)30320-1
doi: 10.1016/j.nbd.2019.104645
pii:
doi:

Substances chimiques

Biomarkers 0
Neurogranin 132654-77-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104645

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Kina Höglund (K)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Disease Research, Neurogeriatrics Division, Karolinska Institutet, Novum, Huddinge, Stockholm, Sweden.

Nathalie Schussler (N)

Sanofi R&D, Rare & Neurologic Diseases Research Therapeutic Area, Neurodegeneration Research, 1 Avenue Pierre Brossolette, Chilly Mazarin 91380, France. Electronic address: nathalie.schussler@sanofi.com.

Hlin Kvartsberg (H)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

Una Smailovic (U)

Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Stockholm, Sweden.

Gunnar Brinkmalm (G)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Victor Liman (V)

Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Bruno Becker (B)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Henrik Zetterberg (H)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK.

Angel Cedazo-Minguez (A)

Sanofi R&D, Rare & Neurologic Diseases Research Therapeutic Area, Neurodegeneration Research, 1 Avenue Pierre Brossolette, Chilly Mazarin 91380, France.

Shorena Janelidze (S)

Clinical Memory Research Unit, Lund University, Sweden.

Isabel A Lefevre (IA)

Sanofi R&D, Rare & Neurologic Diseases Research Therapeutic Area, Neurodegeneration Research, 1 Avenue Pierre Brossolette, Chilly Mazarin 91380, France.

Stéphanie Eyquem (S)

Sanofi R&D, Rare & Neurologic Diseases Research Therapeutic Area, Neurodegeneration Research, 1 Avenue Pierre Brossolette, Chilly Mazarin 91380, France.

Oskar Hansson (O)

Clinical Memory Research Unit, Lund University, Sweden; Memory Clinic, Skåne University Hospital, Skåne, Sweden.

Kaj Blennow (K)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH